Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)

15. juni 2010 oppdatert av: Hellenic Cooperative Oncology Group

Docetaxel Combined With Pulsatile Erlotinib (Tarceva®) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO)

To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating patients with the diagnosis of advanced Non-Small-Lung-Cancer

Studieoversikt

Detaljert beskrivelse

The combination of chemotherapy [such as docetaxel] with continuous administration of targeted drugs which block the molecular machinery of cancer cell growth [such as erlotinib] have failed to improve their efficacy over only-chemotherapy in patients with metastatic lung cancer of the non-small cell histology type. It is not yet known whether administering targeted drugs intermittently could result in improved efficacy of the combinations. This is a multicenter randomized Phase II trial aiming to determine the more active dosing sequence between intermittent erlotinib and docetaxel for treating patients with advanced Non-Small-Lung-Cancer.Patients will be randomly assigned to one of two treatment arms: they will receive a 12-days course of erlotinib either before docetaxel [arm A] or after docetaxel administration [arm B].Treatment will be repeated every 21 days.Patients will be evaluated every 2 cycles (~6 weeks) for response using RECIST criteria. Those patients achieving stable disease or better will continue therapy up to a total 8 cycles. Those patients experiencing progressive disease will be taken off study. Biopsy material will be assessed for biomarkers.

Studietype

Intervensjonell

Registrering (Faktiske)

51

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Athens, Hellas, 11526
        • Sotiria Hospital
      • Athens, Hellas, 11528
        • "Alexandra" Hospital
      • Athens, Hellas, 12461
        • "Attikon" University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic, Oncology Section
      • Athens, Hellas, 14564
        • Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology
      • Athens, Hellas, 15123
        • Hygeia Hospital
      • Ioannina, Hellas, 45500
        • University General Hospital of Ioannina, Medical Oncology Dept
      • Larissa, Hellas, 41110
        • Larissa University Hospital
      • Piraeus, Hellas, 18547
        • Metropolitan Hospital, Second Dept of Medical Oncology
      • Pireaus, Hellas, 18547
        • Metropolitan Hospital, 1st Dept. of Medical Oncology
      • Rio, Patras, Hellas, 26500
        • Patras University Hospital, Dept. of Internal Medicine, Oncology Section
      • Thessaloniki, Hellas, 54007
        • Theagenio Cancer Hospital, 2nd Dept of Medical Oncology
      • Thessaloniki, Hellas, 54007
        • Theagenio Cancer Hospital, 3rd Dept. of Medical Oncology
      • Thessaloniki, Hellas, 56403
        • "Papageorgiou" Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male and female patients aged 18 to 75 years inclusive, with histologically confirmed metastatic NSCLC will be enrolled.
  2. Patients must have not been previously treated with anticancer drugs for advanced disease.
  3. ECOG performance status of 0 - 1.
  4. Life expectancy of at least 12 weeks.
  5. Patients must be able to take oral medication.
  6. At least 4 weeks since any prior major surgery or extended-field radiotherapy. Patients who, in the opinion of the investigator, have fully recovered from limited surgery or have undergone limited-field radiotherapy within 2 weeks may also be considered eligible for the study
  7. Granulocyte count > 1,500/mm3 and platelet count > 100,000/mm3. Haemoglobin ³ 9.0g/dl.
  8. SGOT (AST) and SGPT (ALT) < 2,5 x ULN in the absence of liver metastases or up to 5 x ULN in case of liver metastases
  9. Alkaline phosphatase (ALP) < 2,5 x ULN. If alkaline phosphatase is > 2.5 x ULN, SGOT (AST) and SGPT (ALT) must be < 1.5 x ULN. If alkaline phosphatase is ³ 2.5 x ULN in the presence of liver metastases, SGOT and SGPT must be < 5 x ULN
  10. Serum creatinine <= 1.5 ULN or creatinine clearance > 60 ml/min.
  11. Normal serum calcium.
  12. For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before starting Tarceva/placebo treatment.
  13. Patients with reproductive potential must use effective contraception.
  14. Able to comply with study and follow-up procedures.
  15. Written (signed) Informed Consent to participate in the study.
  16. Written (signed) Informed Consent for use of tumour samples.
  17. Presence of measurable or evaluable disease (lesions that are present but do not fulfil the criteria for measurable disease).
  18. Formalin-fixed, paraffin-embedded tumour tissue samples representative of the tumour will be provided to sponsor within 3 weeks of the patient starting chemotherapy

Exclusion Criteria:

  1. Prior exposure to agents directed at the HER axis (e.g. gefitinib, cetuximab, trastuzumab).
  2. Prior chemotherapy or therapy with systemic anti-neoplastic therapy (e.g., monoclonal antibody therapy) for advanced disease. Prior surgery and/or localised irradiation is permitted.
  3. Patients who have undergone complete tumour resection after responding to platinum based chemotherapy.
  4. Any unstable systemic disease (including active infections, significant cardiovascular disease, [including myocardial infarction within the previous year], any significant hepatic, renal or metabolic disease) metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of study medication(s) or that might affect the interpretation of the results or render the patient at high risk from treatment complications.
  5. Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
  6. Patients are excluded if they have symptomatic brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation; patients with CNS metastases with evidence of stable disease (clinically stable imaging) and stable neurologic function are allowed to enter the study.
  7. Patients who are at risk (in the investigator's opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids are excluded.
  8. Any inflammatory changes of the surface of the eye.
  9. Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease.
  10. Nursing and/or pregnant women.
  11. Hypersensitivity to erlotinib (Tarceva) or to docetaxel or to any of the excipients.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: 1
Erlotinib followed by Docetaxel
Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
Eksperimentell: 2
Docetaxel followed by Erlotinib
Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Progression free survival (PFS)
Tidsramme: Assessment every 6 weeks
Assessment every 6 weeks

Sekundære resultatmål

Resultatmål
Tidsramme
To compare the Overall Survival (OS),the Objective Response Rate (ORR) and duration of response
Tidsramme: Assessment every 6 weeks while on treatment and every 3 months post completion of 8 cycles of treatment until progression
Assessment every 6 weeks while on treatment and every 3 months post completion of 8 cycles of treatment until progression
Identify predictive signaling molecules of the EGFR pathway
Tidsramme: Assessment every 6 weeks while on treatment and every 3 months post completion of 8 cycles of treatment until progression
Assessment every 6 weeks while on treatment and every 3 months post completion of 8 cycles of treatment until progression

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Evangelos Briasoulis, MD, University of Ioannina Hospital, Medical School

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. november 2008

Primær fullføring (Faktiske)

1. mai 2010

Studiet fullført (Faktiske)

1. juni 2010

Datoer for studieregistrering

Først innsendt

30. oktober 2008

Først innsendt som oppfylte QC-kriteriene

30. oktober 2008

Først lagt ut (Anslag)

31. oktober 2008

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

16. juni 2010

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. juni 2010

Sist bekreftet

1. juni 2010

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere